Objective: Several cross-sectional studies have reported an association between visual contrast sensitivity (a functional measure of low contrast vision) and poor cognitive performance or dementia, but no studies have investigated this association prospectively in a population-based cohort with final adjudication of mild cognitive impairment (MCI)/dementia. Methods: In a prospective, community-based study of aging women (Study of Osteoporotic Fractures), we analyzed whether visual contrast sensitivity was associated with increased risk of MCI or dementia and/or worse performance on various cognitive tests assessed 10 years later. Contrast sensitivity was assessed at baseline in each eye using a VISTECH VCTS 6500 wall chart. MCI/dementia was adjudicated by an expert panel. Multivariate logistic and linear regression models were analyzed. Results: Of 1,352 white (88.2%) and African American (11.8%) women with a mean age of 77.7 years (standard deviation 5 3.3), 536 (39.6%) went on to develop MCI/dementia over 10 years. MCI/dementia risk was more than doubled (odds ratio 5 2.16, 95% confidence interval 5 1.58-2.96) in women with the lowest quartile of contrast sensitivity compared to the highest (p < 0.0001 for the linear trend). Reduced baseline contrast sensitivity was also associated with lower performance on several cognitive measures assessed 10 years later. Interpretation: Among older women, reduced contrast sensitivity is associated with a greater risk of MCI/dementia. These findings suggest that visual system neurodegeneration or dysfunction may parallel or precede dementiarelated cortical or subcortical degeneration, and that contrast sensitivity testing may be useful in identifying aging adults at high risk for dementia. ANN NEUROL 2018;83:730-738 A ge-related neurodegenerative diseases, such as Alzheimer disease (AD), are leading causes of death and disability and are expected to affect >100 million people worldwide by 2050.
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1 Abnormal brain pathology can precede cognitive impairment by decades. Accumulation of amyloid-beta plaques may develop years before clinical symptoms in AD, and functional impairment may only become manifest in day-to-day life once substantial neuronal injury has occurred. It is therefore likely that future dementia therapies will be more effective if initiated in presymptomatic individuals. Current methods to identify at-risk individuals for dementia are either very expensive (eg, amyloid imaging) or invasive (eg, lumbar puncture) and present challenges for population-based screening. Development of inexpensive and noninvasive tests to identify those at higher risk for dementia are needed to help stratify those who may benefit most from additional screening. Several cross-sectional studies have shown an association between visual contrast sensitivity, a measurement of visual function, and dementia. [2] [3] [4] [5] Reduced visual contrast sensitivity has also been observed in patients with mild cognitive impairment (MCI), a cognitive decline syndrome that often precedes AD, suggesting that impairment in contrast sensitivity may begin to occur early in the neurodegenerative disease process. 4 Measurement of contrast sensitivity is inexpensive, noninvasive, and rapid, and may be particularly well suited to identify individuals at risk for AD or related neurodegenerative disorders who may benefit from earlier or more invasive evaluations.
In this study, we sought to evaluate whether visual contrast sensitivity, as a simple office-based neurovisual metric, was associated with risk of developing dementia and poor cognitive performance in a well-phenotyped, longitudinal, community-based cohort of aging women. We hypothesized that low visual contrast sensitivity would be associated with development of MCI/dementia and with poor cognitive function 10 years later.
Subjects and Methods

Participants and Cohort
The Study of Osteoporotic Fractures (SOF) is a longitudinal, multisite cohort study that was originally designed to examine predictors of falls and fractures. 6 The cohort has also been utilized to study additional age-related conditions, including dementia. 7, 8 In the total SOF cohort, 10,366 women were originally enrolled, including 9,704 white women enrolled between September 1986 and October 1988, and 662 African American women enrolled between February 1997 and December 1998. Women were excluded if they were unable to walk or had bilateral hip replacements at the time of enrollment. A detailed ophthalmological assessment that included testing of contrast sensitivity in each eye was subsequently added to the protocol and performed at year 10 (which was the study baseline for the African American women). We therefore designated year 10 of the SOF cohort as the baseline for our study. A detailed cognitive assessment and dementia adjudication was performed 10 years later (year 20 of the original SOF cohort). For this analysis, we only included women from the 3 sites that participated in the ancillary cognitive study: Monongahela Valley near Pittsburgh, Pennsylvania; Minneapolis, Minnesota; and Portland, Oregon. Of these 7,760 women, we excluded the 4,516 who died prior to the year 20 study visit and the 876 who terminated participation, were lost to followup, or had minimal information status/missing data. Of the remaining 2,368 women, 1,032 had a clinic examination and 502 underwent an in-home examination that included cognitive testing. We excluded 39 women for indeterminate or missing cognitive data. An additional 98 women with prevalent dementia at baseline (defined by a modified Mini-Mental State Examination [mMMSE] score of < 20 [range 5 0-26], self-reported dementia, and/or already taking AD medications) and 45 women with no contrast sensitivity data were excluded. This led to a final sample for this analysis of 1,352 women.
The study was approved by the institutional review boards at each clinic as well as the coordinating center of University of California, San Francisco and California Pacific Medical Center. All participants provided written informed consent.
Contrast Sensitivity and Other Ophthalmological Assessments
Contrast sensitivity, a functional measure of low contrast vision, was assessed using a VISTECH (Hartford, CT) VCTS 6500 wall chart and light meter. The VISTECH system presents a series of sine wave gratings at calibrated levels of contrast. A light meter was used to measure and enable standardized illumination (target 50-70 footlamberts given that this was an older population), and sites were instructed to test subjects in areas of uniform illumination. The testing distance was 10ft from the chart, with the middle of the chart around eye level. Subjects were tested with their glasses on if they wore glasses for distance; no other correction was made for potential refractive error. Study subjects were instructed to report whether a grating was visible, and if it was visible, the orientation of the grating. At the 10ft distance, the spatial frequencies tested on each line are 1.5, 3, 6, 12, and 18 cycles per degree. The highest spatial frequency that subjects could accurately report in each line was scored. The averages of each line were plotted against a contrast sensitivity curve, to yield a score between 0 (worst) and 150 (best). For our primary analysis, we averaged contrast sensitivity between eyes; in a sensitivity analysis, we also examined contrast sensitivity in the worst eye. Self-reported age-related macular degeneration (AMD), glaucoma, and cataract were evaluated in other sensitivity analyses.
MCI/Dementia Adjudication and Cognitive Assessments
Ten years after visual contrast sensitivity testing in each eye, participants underwent a battery of cognitive tests. This included an assessment of global cognition (3MS), verbal memory (California Verbal Learning Test II, short form [CVLT]), executive function (Trails B, Digit Span Forward, Digit Span Backward), and semantic memory (category and verbal fluency). 7 Dementia and MCI diagnosis was determined using a 2-stage process. First, participants were screened for cognitive impairment using the expanded neuropsychological test battery. Those who screened negative were considered cognitively normal. Those who screened positive were further clinically adjudicated by a panel of clinical experts. Criteria for a diagnosis of dementia were based on the Diagnostic and Statistical Manual of Mental Disorders, 4th edition 9 and that of MCI were based on modified Peterson criteria. 10 Further details on dementia/ MCI diagnosis in this cohort have been published elsewhere.
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Other Measurements
Each participant completed a questionnaire and was asked at the year 10 study visit (baseline for this analysis) about selfreported health, smoking status, and alcohol use in the past 30 days. Women were also queried about a physician diagnosis of medical conditions including myocardial infarction, stroke, diabetes, and hypertension. The mMMSE was administered.
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Depressive symptoms were evaluated using the Geriatric Depression Scale (GDS). 13 Body mass index (BMI) was calculated using measures of body weight and height. Participants were queried about race/ethnicity and education at the time of initial SOF enrollment.
Statistical Analysis
For the primary analysis, multivariate logistic regression was used to analyze whether contrast sensitivity at baseline was associated with the development of MCI/dementia 10 years later. A multivariate model adjusting for factors that could potentially relate to both contrast sensitivity and cognition and based on prior literature, including age, race, education, BMI, history of stroke, myocardial infarction, hypertension, or diabetes, current smoking, current alcohol use (any drinks in the past 30 days), mMMSE, and GDS was also conducted. For the primary analysis, average contrast sensitivity of both eyes was used. Additional sensitivity analyses were performed by analyzing contrast sensitivity from the worst eye only. For secondary analyses, we also analyzed whether cognitive tests were different among quartiles of contrast sensitivity at baseline using a general linear regression model. Nonlinear modeling was examined using Lowess and cubic splines. An alpha of < 0.05 was considered statistically significant. SAS (v9.4; SAS Institute, Cary, NC) was used for the final analysis.
Results
Baseline Characteristics
Of the 1,352 women, the mean age was 77.7 years (standard deviation [SD] 5 3.3) at the baseline visit for this analysis, 11.8% were African American, and mean education was 12.9 years (SD 5 2.5). Ten years later, 536 (39.6%) women had developed MCI/dementia. At baseline, the MCI/dementia group was slightly older, more likely to be African American, reported a lesser amount of alcohol use in the past month, and had a higher rate of depression, a lower education level, and a slightly lower mMMSE. Table 1 reports baseline characteristics based on quartile of contrast sensitivity. Baseline cognitive testing with mMMSE and Trails B showed slightly lower scores in women with lower baseline visual contrast sensitivity. . Analysis of a model using contrast sensitivity in the worst eye (rather than averaging both eyes) did not significantly change the results (see Table  2 ). Examination of the association between contrast sensitivity and dementia using nonlinear modeling, including Lowess and cubic splines, showed no substantial improvement of the fit compared to linear modeling. Glaucoma and AMD reduce contrast sensitivity and have been previously associated with dementia. [14] [15] [16] [17] [18] The association between contrast sensitivity and MCI/ dementia remained after excluding for women with baseline self-reported glaucoma (p < 0.0001 for trend in OR per quartile) or excluding baseline self-reported AMD (p < 0.0001 for trend in OR per quartile; see Table 2 ). Cataract can also reduce contrast sensitivity. Excluding women with self-reported cataract (n 5 425 analyzed), the association between contrast sensitivity and MCI/ dementia remained (p < 0.004 for the trend in the OR per quartile for the unadjusted model), although the sample size was substantially smaller (see Table 2 ).
Decreased Contrast Sensitivity Is Associated with Worse Cognitive Performance 10 Years Later As a secondary analysis, we examined whether baseline contrast sensitivity averaged from both eyes was associated with cognitive performance 10 years later (Table 3) . In an unadjusted model, lower baseline contrast sensitivity was associated with a lower performance on the 3MS, Trails B, CVLT (10-minute recall), digit span backward, verbal fluency, and category fluency. Contrast sensitivity was not associated with digit span forward. After further adjustment for other dementia risk factors, including alcohol use, diabetes, hypertension, and depression, the associations were attenuated but remained significant for Trails B and CVLT and were borderline significant for 3MS (p 5 0.05).
Discussion
In a cohort of 1,352 community-dwelling older women, reduced contrast sensitivity was associated with a greater risk of development of MCI/dementia within 10 years. These associations were independent of other known risk factors of MCI/dementia, such as age, education, smoking, and race. These associations were not significantly affected by adjusting for a self-described history of glaucoma, AMD, or cataract. These findings support the use of contrast sensitivity testing as part of a multimodal panel to identify healthy aging adults at highest risk for dementia. These findings also support the hypothesis that neurodegeneration or dysfunction in the visual system may parallel or precede the cortical or subcortical degeneration that leads to clinical dementia.
Cross-sectional studies have previously demonstrated that patients with dementia exhibit impairment in visual contrast sensitivity. Using frequency doubling technology to assess contrast sensitivity in the visual field, Risacher et al observed reduced contrast sensitivity in subjects with AD or MCI compared to healthy controls. 4 Similar observations were seen in AD patients using different methods to evaluate contrast sensitivity. 3, [19] [20] [21] [22] [23] Because contrast sensitivity depends on brain networks that can be affected in AD and other dementias, one explanation for these observations is that the association could be secondary to widespread neurodegenerative changes in later stage dementia or even difficulties in performing and reporting the task. An early analysis from the SOF cohort, published in 2004, reported an association between high-contrast visual acuity and reduced performance on the MMSE and functional decline, but this was before adjudication for MCI/dementia in the cohort was completed. 24 Contrast sensitivity is a more sensitive tool than visual acuity testing to identify subclinical impairment of visual function. 25 In patients with glaucoma, changes in contrast sensitivity can be detected earlier than changes in visual acuity, 26 and in patients with AMD changes in contrast sensitivity correlate better with real-world function and prognosis. 27 Using a contrast sensitivity-based cutoff as a measure of poor visual function, Fischer et al showed that poor visual function was associated with future reduced MMSE scores and a self-reported history of dementia 10 years later in a separate community-dwelling cohort of aging individuals. 28 We now show that reduced contrast sensitivity precedes development of dementia at 10 years of longitudinal follow-up in a well-phenotyped, prospective, communitybased cohort. Impaired contrast sensitivity can be caused by injury throughout the visual system, including the cornea, anterior chamber, lens, vitreous, retina, optic nerve, anterior visual pathways, posterior visual pathways, and higher level cortical processing. We attempted to evaluate whether specific ocular pathologies in select localizations on the causal pathway, including self-reported glaucoma, AMD, and cataract, could have contributed to the observed association between contrast sensitivity and MCI/dementia and cognitive performance but did not observe any association. However, as these conditions were based on self-report, our ability to address this possibility was limited. Furthermore, as a number of other ophthalmological conditions were not formally assessed in these subjects and the majority of the cohort did not undergo detailed ophthalmological study evaluations, this dataset does not allow for localization of where in the visual system the impaired contrast sensitivity in these women originates. On the clinical level, the inclusion of patients without a detailed ophthalmologic evaluation could also be considered a strength of this study when considering the potential application of visual contrast sensitivity as a screening tool. The use of existing refraction also reflects a practical, real-world approach that is not confounded by a requirement that patients undergo additional testing.
The presence of reduced contrast sensitivity years before clinical onset of dementia suggests that this association is not simply a consequence of later stage dementia and that reduced contrast sensitivity can precede clinical onset of dementia and may even precede frank cortical or subcortical neurodegeneration in some cases. The mechanistic underpinnings of impaired visual function in the setting of early stage neurodegenerative diseases remain unclear and may be multifactorial. Retinal neuron loss occurs in patients with AD, 29, 30 and retinal thinning can be noninvasively detected in living individuals with MCI and AD. 31 Retinal amyloid deposition has been reported in AD patients, 32 but several follow-up studies did not confirm this pathology. 33, 34 Other areas of the visual system also degenerate in AD, such as the lateral geniculate nucleus and visual cortex, and could contribute to impaired contrast sensitivity. [35] [36] [37] Microvascular disease, a risk factor for both dementia and chronic vision loss, may also play a causal role in our observed findings. 38, 39 AD is the most common cause of dementia in aging adults and is associated with an early selective decline in memory function. Hippocampal volume has been associated with retinal nerve fiber layer thickness on optical coherence tomography in healthy elderly subjects without demonstrated dementia. 40 The MCI/dementia adjudication in our study was made clinically, and there was no collection of cerebrospinal fluid (CSF) biomarkers or neuroimaging to evaluate for amyloid/tau or other pathologies. If we assume that AD is the most common cause of dementia in our cohort, and if reduced low contrast acuity was specific for predicting AD pathology, it might be expected that there would be a selective association between low contrast acuity and tests of short-term memory function. However, in this analysis, low contrast sensitivity was associated with reduced future cognitive performance in several domains, including those involved in memory, executive functioning, and language. Future studies will be helpful in clarifying whether contrast sensitivity is most useful in predicting specific causes of dementia. New methods of testing visual function are rapidly being developed, including those that allow for repeated measures in home-based settings. 20 Such measures may improve the accuracy of contrast sensitivity testing and improve its ability to predict MCI/dementia. Technological advances in visual function testing may also increase accessibility and the generalizability of this strategy for dementia risk screening. Our study has important limitations. The SOF cohort included mostly white women. In future studies, it will be invaluable to analyze whether the association between contrast sensitivity and future MCI/dementia is generalizable to men and to people of other racial/ethnic and geographic backgrounds. Our study population was also relatively old (mean age 5 78 years at the baseline for this analysis and nearly 88 years at the time of dementia adjudication), and these results may not apply in younger adults. The 39% conversion rate to dementia that was observed in our cohort is consistent with other studies of dementia incidence in the oldest old age group.
11,41-43 MCI/dementia adjudication in our study was made clinically, and future analyses could benefit from the addition of CSF biomarkers or neuroimaging to support more specific dementia pathologies, as well as additional longitudinal assessments of cognitive performance to analyze associations of visual contrast sensitivity with rates of cognitive decline. There may also be unmeasured biases in sample selection due to mortality, loss to follow-up, or inability to assess for MCI/dementia. Localization of contrast sensitivity deficits to particular ocular pathologies in future studies will also be important for understanding potential mechanisms driving the observed association between contrast sensitivity impairment and future dementia. In summary, these data support an association between impaired contrast sensitivity and future MCI/ dementia. If these observations are confirmed and validated, contrast sensitivity has the potential to provide a noninvasive way of identifying aging adults at greatest risk of developing dementia, which could be incorporated as part of a multimodal risk assessment.
